{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:33:25Z","timestamp":1789468405876,"version":"build-2803163510"},"reference-count":26,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chinese National Health Association"},{"name":"Daiichi Sankyo (China) Holding Co., Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Introduction: Altered lipid metabolism is implicated in atrial fibrillation, but longitudinal lipidomic changes during anticoagulation remain poorly characterized. Objectives: To characterize plasma lipidomic changes during 12 weeks of edoxaban treatment and explore associated metabolic pathways in Chinese patients with nonvalvular atrial fibrillation (NVAF). Methods: This prespecified substudy of a prospective multicenter study analyzed fasting predose plasma collected at baseline and week 12 from 74 patients receiving protocol-assigned edoxaban doses (15 mg, n = 3; 30 mg, n = 23; 60 mg, n = 48). Widely targeted UPLC-MS\/MS lipid profiling, with laboratory quality control (QC CV &lt; 30%), yielded 1099 lipid features retained for statistical analysis. Differential lipids were defined by paired testing with Benjamini\u2013Hochberg correction (|log2FC| &gt; 0.58 and q &lt; 0.05). Results: The overall, 30 mg, and 60 mg analyses identified 25, 15, and 35 FDR-significant features, respectively; none was significant in the exploratory 15 mg group. Twelve features were shared across the primary analyses and increased at week 12; they comprised mainly acylcarnitines, together with docosadienoic acid and DG (21:0\/16:0\/0:0), and four lacked HMDB identifiers. The corresponding FDR panels yielded participant-grouped out-of-fold AUCs of 0.918 (95% CI 0.890\u20130.963), 0.786 (0.701\u20130.890), and 0.891 (0.835\u20130.950) for discriminating baseline from week 12, respectively. Pathway mapping identified no multi-compound enriched pathways (q &lt; 0.05). Observed annotations represented single-metabolite signals\u2014most notably DG (21:0\/16:0\/0:0) (HMDB0094301) and octanoylcarnitine (HMDB0000791)\u2014rather than coordinated, pathway-level alterations. Conclusions: Paired analyses identified consistent longitudinal plasma lipidomic changes in patients receiving edoxaban. The 12 shared features provide focused candidates for targeted validation. Controlled studies are needed to determine whether these changes are specific to edoxaban and to establish their biological and clinical relevance.<\/jats:p>","DOI":"10.3390\/metabo16090672","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:39:24Z","timestamp":1789137564000},"page":"672","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Plasma Lipidomic Changes in Chinese Patients with Nonvalvular Atrial Fibrillation During 12 Weeks of Edoxaban Treatment"],"prefix":"10.3390","volume":"16","author":[{"given":"Cheng","family":"Cui","sequence":"first","affiliation":[{"name":"Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhao","family":"Chen","sequence":"additional","affiliation":[{"name":"Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China"},{"name":"School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haodi","family":"Chai","sequence":"additional","affiliation":[{"name":"Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0608-8192","authenticated-orcid":false,"given":"Dongyang","family":"Liu","sequence":"additional","affiliation":[{"name":"Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Deng, Y., Dai, S., Zhu, S., Jiang, J., Chai, L., Liu, Z., Qian, X., Chong, L., Hu, S., and Gao, Y. (2026). Edoxaban population pharmacokinetics in Chinese patients with nonvalvular atrial fibrillation: Model-informed dose adjustment. Thromb. Haemost., online ahead of print.","DOI":"10.1055\/a-2802-3641"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e012853","DOI":"10.1161\/JAHA.119.012853","article-title":"Plasma ceramides and sphingomyelins in relation to atrial fibrillation risk: The Cardiovascular Health Study","volume":"9","author":"Jensen","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e000889","DOI":"10.1161\/JAHA.114.000889","article-title":"Plasma phospholipid saturated fatty acids and incident atrial fibrillation: The Cardiovascular Health Study","volume":"3","author":"Fretts","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13105-023-00958-0","article-title":"Plasma lipidome and risk of atrial fibrillation: Results from the PREDIMED trial","volume":"79","author":"Toledo","year":"2023","journal-title":"J. Physiol. Biochem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.amjcard.2016.08.010","article-title":"Metabolomic profiling in relation to new-onset atrial fibrillation (from the Framingham Heart Study)","volume":"118","author":"Ko","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.amjcard.2019.03.017","article-title":"Serum metabolomics and incidence of atrial fibrillation (from the Atherosclerosis Risk in Communities Study)","volume":"123","author":"Alonso","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11306-019-1557-7","article-title":"Comprehensive metabolomic and proteomic analyses reveal candidate biomarkers and related metabolic networks in atrial fibrillation","volume":"15","author":"Zhou","year":"2019","journal-title":"Metabolomics"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lu, C., Liu, C., Mei, D., Yu, M., Bai, J., Bao, X., Wang, M., Fu, K., Yi, X., and Ge, W. (2022). Comprehensive metabolomic characterization of atrial fibrillation. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.911845"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.yjmcc.2024.10.011","article-title":"Metabolomics in atrial fibrillation\u2014A review and meta-analysis of blood, tissue and animal models","volume":"197","author":"Wijdeveld","year":"2024","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e13853","DOI":"10.7717\/peerj.13853","article-title":"Application of plasma metabolome for monitoring the effect of rivaroxaban in patients with nonvalvular atrial fibrillation","volume":"10","author":"Zhao","year":"2022","journal-title":"PeerJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1194\/jlr.D700041-JLR200","article-title":"Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics","volume":"49","author":"Matyash","year":"2008","journal-title":"J. Lipid Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7608","DOI":"10.1021\/acs.analchem.8b01331","article-title":"Development of a high coverage pseudotargeted lipidomics method based on ultra-high performance liquid chromatography-mass spectrometry","volume":"90","author":"Xuan","year":"2018","journal-title":"Anal. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11306-007-0082-2","article-title":"Proposed minimum reporting standards for chemical analysis: Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI)","volume":"3","author":"Sumner","year":"2007","journal-title":"Metabolomics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11306-020-01728-5","article-title":"Dissemination and analysis of the quality assurance (QA) and quality control (QC) practices of LC\u2013MS based untargeted metabolomics practitioners","volume":"16","author":"Evans","year":"2020","journal-title":"Metabolomics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1038\/s41596-020-0341-5","article-title":"Development of a plasma pseudotargeted metabolomics method based on ultra-high-performance liquid chromatography\u2013mass spectrometry","volume":"15","author":"Zheng","year":"2020","journal-title":"Nat. Protoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11306-016-1030-9","article-title":"Non-targeted UHPLC-MS metabolomic data processing methods: A comparative investigation of normalisation, missing value imputation, transformation and scaling","volume":"12","author":"Engel","year":"2016","journal-title":"Metabolomics"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"van den Berg, R.A., Hoefsloot, H.C.J., Westerhuis, J.A., Smilde, A.K., and van der Werf, M.J. (2006). Centering, scaling, and transformations: Improving the biological information content of metabolomics data. BMC Genom., 7.","DOI":"10.1186\/1471-2164-7-142"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: A practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"ref_22","first-page":"2825","article-title":"Scikit-learn: Machine learning in Python","volume":"12","author":"Pedregosa","year":"2011","journal-title":"J. Mach. Learn. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"D622","DOI":"10.1093\/nar\/gkab1062","article-title":"HMDB 5.0: The Human Metabolome Database for 2022","volume":"50","author":"Wishart","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"D478","DOI":"10.1093\/nar\/gkt1067","article-title":"SMPDB 2.0: Big improvements to the Small Molecule Pathway Database","volume":"42","author":"Jewison","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jacc.2007.09.055","article-title":"Combined metabolomic and proteomic analysis of human atrial fibrillation","volume":"51","author":"Mayr","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Liu, W., Hu, B., Wang, Y., Zhang, X., Zhu, M., Shi, Y., Guo, C., and Zhang, Y. (2023). Multiple targets related to mitochondrial function unveiled by metabolomics and proteomics profiles of hearts from atrial fibrillation patients. Front. Physiol., 14.","DOI":"10.3389\/fphys.2023.1123391"}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/9\/672\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:00:51Z","timestamp":1789462851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/9\/672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["metabo16090672"],"URL":"https:\/\/doi.org\/10.3390\/metabo16090672","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}